Brain Connectivity in Depression

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Brigham and Women's Hospital
Study ID
NCT03276793
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MRI scan — OTHER
    Patients will undergo an MRI scan
  • Behavioral testing — BEHAVIORAL
    Patients will complete a series of cognitive tasks

Study Details

This study originally included 140 subjects with medication-refractory depression undergoing 10 Hz transcranial magnetic stimulation (10Hz-TMS) to the left dorsal lateral prefrontal cortex (DLPFC), with the goal of having 60 completers with good quality data. Subjects were recruited from the TMS clinics at Beth Israel Deaconess Medical Center, Brigham \& Women's Hospital, and Butler Hospital. Subjects underwent an hour-long MRI scanning session, an optional DNA-sample collection, up to three 20 minute neuronavigation sessions for marking the site of TMS stimulation, questionnaires, and a behavioral testing battery before and after their TMS treatment course. The task battery included the Emotion Conflict Resolution (ECR) task, Multi-Source Interference Task (MSIT), War Game (Gambling) task, and Associative Learning with Reversal task. Subjects' scores on the Quick Inventory of Depressive Symptomatology (QIDS) and Beck Depression Inventory (BDI) were assessed before and after the TMS course. MRI data was utilized to identify brain regions whose connectivity to the stimulation site co-varies with the aforementioned measures of symptom improvement. This was the only study group until August 30, 2022, and the primary outcome was analyzed for the 10Hz-TMS group. Due to changes in clinical standard of care from 10Hz-TMS to a newer version of TMS termed intermittent theta burst (iTBS), in September 2022 a second group was added to include patients receiving this new form of TMS. This second group included another 100 patients with medication-refractory depression undergoing iTBS to the left dorsal lateral prefrontal cortex (DLPFC), with the intent to have 80 completers. Massachusetts General Hospital was added as a data collection site in lieu of Butler Hospital. Subjects will undergo an hour-long MRI scanning session, up to three 20 minute neuronavigation sessions for marking the site of TMS stimulation, questionnaires, and a behavioral testing battery before and after their TMS treatment course. The task battery will included the Emotion Conflict Resolution (ECR) task, Multi-Source Interference Task (MSIT), Penn Emotion Recognition Test, the Suicide/Death Implicit Association Test, and Associative Learning with Reversal task. Subjects' scores on the Beck Depression Inventory (BDI) were assessed before and after the TMS course. MRI data will be utilized to identify brain regions whose connectivity to the stimulation site co-varies with the aforementioned measures of symptom improvement. Due to a higher dropout rate than anticipated, in March of 2025 an amendment was added to include an additional 20 subjects in the second group's enrollment goal to increase the likelihood of achieving 80 completers.

Key Dates

Start date
Apr 3, 2018
Status verified
Apr 2025
Primary completion
Sep 30, 2027
Completion
Oct 31, 2027

Study Design

Enrollment
260 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: MRI and behavioral assessment for patients receiving TMS
    Subjects will undergo an hour-long MRI scanning session, a marking for the site of planned clinical TMS stimulation and a behavioral testing battery before and after their TMS treatment course.

Primary Outcome Measure

Prediction of repetitive Transcranial Magnetic Stimulation (rTMS) clinical response [ Time Frame: 1 year after study completion ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
Beth Israel Deaconess Medical CenterBostonMassachusetts02215-
Brigham and Women's HospitalBostonMassachusetts02115
Michael D Fox, MD, PhD
617-732-7432
Michael D Fox, MD, PhD (PRINCIPAL_INVESTIGATOR)
Joseph J Taylor, MD, PhD (SUB_INVESTIGATOR)
Shan H Siddiqi, MD (SUB_INVESTIGATOR)
Stephan T Palm, BS (SUB_INVESTIGATOR)
Christopher Lin, BS (SUB_INVESTIGATOR)
Dania Haj-Darwish, BS (SUB_INVESTIGATOR)
Summer B Frandsen, BS (SUB_INVESTIGATOR)
William Drew, BA (SUB_INVESTIGATOR)
Sanaz Khosravani, PhD (SUB_INVESTIGATOR)
David W Lawson, BA (SUB_INVESTIGATOR)
Emma Jones, BS (SUB_INVESTIGATOR)
Massachusetts General HospitalBostonMassachusetts02129
Tracy A Barbour, MD
617-726-5340
Luke Janak, BS
Tracy A Barbour, MD (PRINCIPAL_INVESTIGATOR)
Joan A Camprodon, MD, MPH, PhD (PRINCIPAL_INVESTIGATOR)
Nicole L Brocious, BS (SUB_INVESTIGATOR)
Christopher J Funes, MS (SUB_INVESTIGATOR)
James R Coleman, BS (SUB_INVESTIGATOR)
Anna Moser, MS (SUB_INVESTIGATOR)
Olivia J Newman, BS (SUB_INVESTIGATOR)
Astrid Warney, MS (SUB_INVESTIGATOR)
Stephanie R Kramer, BS (SUB_INVESTIGATOR)
Butler HospitalProvidenceRhode Island02906-

Find similar trials in Boston, MA

By condition

Related Studies